- Home
- INTR vs ICUI Comparison
INTR vs ICUI Comparison
Compare INTR & ICUI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTR
- ICUI
- Stock Information
- Founded
- INTR 1994
- ICUI 1984
- Country
- INTR Brazil
- ICUI United States
- Employees
- INTR N/A
- ICUI N/A
- Industry
- INTR
- ICUI Medical/Dental Instruments
- Sector
- INTR
- ICUI Health Care
- Exchange
- INTR Nasdaq
- ICUI Nasdaq
- Market Cap
- INTR 3.0B
- ICUI 3.4B
- IPO Year
- INTR N/A
- ICUI 1992
- Fundamental
- Price
- INTR $7.42
- ICUI $127.74
- Analyst Decision
- INTR Buy
- ICUI Strong Buy
- Analyst Count
- INTR 3
- ICUI 5
- Target Price
- INTR $5.97
- ICUI $196.75
- AVG Volume (30 Days)
- INTR 1.8M
- ICUI 198.1K
- Earning Date
- INTR 08-06-2025
- ICUI 08-06-2025
- Dividend Yield
- INTR 1.07%
- ICUI N/A
- EPS Growth
- INTR 97.58
- ICUI N/A
- EPS
- INTR 0.40
- ICUI N/A
- Revenue
- INTR $860,720,325.00
- ICUI $2,420,093,000.00
- Revenue This Year
- INTR $80.32
- ICUI N/A
- Revenue Next Year
- INTR $17.51
- ICUI N/A
- P/E Ratio
- INTR $18.79
- ICUI N/A
- Revenue Growth
- INTR 39.90
- ICUI 7.22
- 52 Week Low
- INTR $3.88
- ICUI $111.97
- 52 Week High
- INTR $7.84
- ICUI $196.26
- Technical
- Relative Strength Index (RSI)
- INTR 60.50
- ICUI 39.54
- Support Level
- INTR $6.99
- ICUI $125.78
- Resistance Level
- INTR $7.30
- ICUI $133.85
- Average True Range (ATR)
- INTR 0.23
- ICUI 3.34
- MACD
- INTR 0.02
- ICUI -0.32
- Stochastic Oscillator
- INTR 79.31
- ICUI 15.71
About INTR Inter & Co. Inc.
Inter & Co Inc operates as a digital bank. The company's segment includes Banking & Spending; Investments; Insurance Brokerage; and Inter Shop. It generates maximum revenue from the Banking & Spending segment which comprises a wide range of banking products and services, such as checking accounts, cards, deposits, loans and advances, and other services, which are available to the clients by means of Inter's mobile application.
About ICUI ICU Medical Inc.
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (43% of consolidated revenue), infusion systems (28%), and vital care (29%). The combined entity remains primarily US-focused, generating over 63% of its sales domestically.